Investor Presentaiton

Launching Timeline by Product Europe US Europe US Remsima Infliximab INFLECTRA JAFL X MAS Truxima Rituximab Herzuma Trastuzumab 2013 2016 2017 2018 INFLECTRA INFLIXIMAB Vegzelma bevacizumab 2022 2023(E) Vegzelma Yuflyma Note: 1) The logo of Inflectra™ is owned by Pfizer 2) Launching plan could be subjective to the approval bevacizumab adalimumab Regkirona regdanvimab Remsima Infliximab SUBCUTANEOUS Yuflyma adalimumab 2019 2020 2021 Truxima Herzuma® Rituximab Trastuzumab CT-P43 CT-P39 CT-P41 CT-P42 CT-P47 bStelara bXolair bProlia bEylea bActemra 2024(E) 2025(E) 2026(E) Remsima CT-P41 CT-P39 CT-P47 Infliximab SUBCUTANEOUS bProlia bXolair bActemra CT-P43 CT-42 bStelara bEylea Investor Relations 2022 15

View entire presentation